Divine Aleru, Microbiome Signatures Research Coordinator

This review assesses the safety of vaginal hormones and SERMs in treating genitourinary menopausal symptoms in breast cancer survivors. It finds no significant rise in serum estrogen levels or an increased risk of breast cancer recurrence, but more extensive studies are needed to confirm these findings.

This review highlights the lack of conclusive evidence on the safety of hormone replacement therapy (HRT) in women treated for early-stage endometrial cancer. While a small study found no significant increase in cancer recurrence risk, the low quality of the evidence leaves uncertainty about the benefits and risks of HRT use in these women.

This study shows that menopausal hormone therapy increases the risk of gallstones, especially with topical estrogen and tibolone. However, no increased risk for gallbladder cancer was found. These findings underscore the need for caution in prescribing hormone therapy, particularly for women with higher gallstone risk factors.

Long-term use of estrogen and estrogen-progestin therapies significantly increases the risk of endometrial cancer, particularly for women with lower BMI. The risk is dose-dependent, with continuous-combined therapy having complex effects based on body weight.

This review offers updated guidance on the use of menopausal hormone therapy, highlighting its benefits when started early, particularly for women with low cardiovascular risk. It stresses the importance of individualized care and decision-making when considering HT for managing menopausal symptoms.

This review investigates the stroke risk associated with hormonal therapies in postmenopausal women, comparing oral and transdermal estrogen formulations and highlighting the need for individualized treatment plans based on age and cardiovascular health.

This review explores the thrombosis risks of hormonal therapies, comparing various estrogen formulations and progestins. It emphasizes the need for personalized treatment based on thrombophilic risk factors, highlighting the safer options such as transdermal estrogen and progestin-only therapies.

This study explores estrogen’s effects on thrombosis risk in hormonal contraceptives and HRT, highlighting mechanisms of action, the role of different estrogen doses, and the importance of individualized risk assessments in preventing thromboembolic events.

This study examines estrogen’s dual role in breast cancer, focusing on its effects on estrogen receptor-positive cancers and how different therapies, such as SERMs and aromatase inhibitors, mitigate risks while highlighting estrogen metabolism’s role in cancer risk.

The study emphasizes the risks and benefits of menopausal hormone therapy in managing vasomotor symptoms, osteoporosis, and cardiovascular health. It highlights the importance of timing, formulation, and route of administration in optimizing therapy for individual patients.

This review emphasizes the benefits and risks of MHT in managing menopause symptoms, including the prevention of long-term conditions. It advocates for individualized treatment plans, especially focusing on the timing of initiation.

This guideline on menopausal symptom treatment prioritizes early initiation of hormone therapy, safe routes like transdermal estradiol, and vaginal care for genitourinary symptoms. It promotes a tailored approach considering cardiovascular and breast cancer risks.

The review defines menopause vasomotor symptoms treatment and microbiome relevance, favors timely hormone therapy and transdermal routes, details effective nonhormone options, and highlights neurokinin antagonists for fast relief while separating vasomotor and genitourinary care for microbiome-aware practice.

This review sets a simple plan for menopausal hormone therapy first-line management, favors transdermal routes when risk exists, and backs local therapy for genitourinary symptoms with clear links to vaginal ecosystem health.

The review shows that menopausal hormone therapy osteoporosis prevention lowers fractures when started near menopause, favors transdermal routes for safety, and maps RANKL–OPG and cytokine shifts with clear microbiome relevance despite no direct microbiota data.

The guideline links menopausal hormone therapy guidelines and vaginal microbiome care to safer symptom control, better GSM outcomes, and lower UTI risk through local estrogen, with timing and route choices that manage vascular and endometrial risk.

The review defines progesterone endometrial tumor suppressor mechanisms, links receptor biology to therapy response, and outlines immune and barrier changes with clear microbiome relevance despite no direct taxa reporting.

This review links menopausal hormone therapy and vaginal microbiome care to safer symptom relief, bleeding control, and prevention. It favors transdermal estradiol and physiologic progestogens, and it highlights estriol plus lactobacilli for urogenital symptoms with minimal systemic exposure.

With the growing understanding of the intratumoral microbiota’s influence on cancer progression, the next frontier in cancer therapy is microbiota-targeted interventions. By introducing beneficial microbes or altering existing microbial populations within tumors, therapies can be designed to modulate the immune system, promote tumor suppression, and improve drug efficacy. However, challenges remain in deciphering the complex relationships between microbes, tumor cells, and the immune system, necessitating more refined research methods and standardized approaches to translate these discoveries into clinical practice.

This study demonstrates the potent anticancer effects of a tumor-resident bacterial consortium in both immunocompetent and immunocompromised mice. The consortium induces tumor remission through selective thrombosis, necrosis, and biofilm formation, offering a promising drug-free strategy for cancer therapy with potential applications in treating solid tumors.

The review examines the therapeutic potential of FMT and next-generation microbiome therapies in treating metabolic disorders. It highlights the promising role of FMT in restoring microbial balance and improving conditions like obesity and type 2 diabetes, though challenges remain in optimizing treatment protocols.

This review examines the immunomodulatory effects of probiotics, detailing how they enhance immune functions through interactions with immune cells in the gut. Probiotics help regulate cytokine release, boost IgA production, and support gut health, offering potential therapeutic benefits for immune disorders.

The review discusses the impact of gut microbiota on cancer therapy outcomes, focusing on chemotherapy and immunotherapy. It highlights how microbiota influences drug effectiveness and immune responses, emphasizing the potential of microbiota modulation for personalized treatment approaches.

This review emphasizes how gut microbiota influences cancer chemotherapy efficacy and toxicity. It discusses microbial species, metabolites, and strategies to optimize chemotherapy response, suggesting that microbiota modulation could improve treatment outcomes.